--- title: Why Simsen | A ctDNA partner that speaks your language description: Whether you run trials, research or a clinic, Simsen meets you where you are and delivers ctDNA results you can act on. See why teams choose Simsen. image: https://simsendiagnostics.com/hubfs/simsen-og-why-simsen.png --- [Skip to the main content.](https://simsendiagnostics.com/why-simsen#main-content) [![Simsen logotype](https://simsendiagnostics.com/hs-fs/hubfs/SD_logo%20medium-2.png?width=588&height=164&name=SD_logo%20medium-2.png "Simsen logotype")](https://simsendiagnostics.com?hsLang=en) [![Simsen logotype](https://simsendiagnostics.com/hs-fs/hubfs/SD_logo%20medium-2.png?width=588&height=164&name=SD_logo%20medium-2.png "Simsen logotype")](https://simsendiagnostics.com?hsLang=en) - [PLATFORM](https://simsendiagnostics.com/platform) - [Why Simsen](https://simsendiagnostics.com/why-simsen) - [Our technology](https://simsendiagnostics.com/platform-our-technology) - [Methodology](https://simsendiagnostics.com/platform-methodology) - [Find your approach](https://simsendiagnostics.com/find-your-approach) - [Delivered your way](https://simsendiagnostics.com/both-delivery-models) - [Solutions](https://simsendiagnostics.com/solutions-overview) - [EVIDENCE](https://simsendiagnostics.com/evidence-hub) - [Publications](https://simsendiagnostics.com/evidence-publications) - [Paediatric solid tumours](https://simsendiagnostics.com/evidence-paediatric-solid-tumours) - [CNS tumours & CSF ctDNA](https://simsendiagnostics.com/evidence-cns-csf-ctdna) - [White papers](https://simsendiagnostics.com/evidence-white-paper-ctdna-trials) - [COMPANY](https://simsendiagnostics.com/company-about) - [About us](https://simsendiagnostics.com/company-about) - [Team](https://simsendiagnostics.com/company-team) - [Contact us](https://simsendiagnostics.com/company-contact) - [News](https://simsendiagnostics.com/news) - [RESOURCES](https://simsendiagnostics.com/resources-hub) - [Sample collection guides](https://simsendiagnostics.com/resources-sample-collection-guides) - [Baseline kit guide](https://simsendiagnostics.com/baseline-collection-kit) - [Follow-up kit guide](https://simsendiagnostics.com/resources-followup-collection-kit) Search [![Request a conversation](https://hubspot-no-cache-eu1-prod.s3.amazonaws.com/cta/default/25734893/interactive-412216133822.png)](https://simsendiagnostics.com/hs/cta/wi/redirect?encryptedPayload=AVxigLI1AWeK9%2FmXQcEF4ftmAPshFd4S580Jel%2FweBTsGsgqXdHWCDRoauEhOtNx80XRb8O96rI6cwBaWFkVISbd46oDDS1bDylKAfW6ERCgn%2FHz1CmawL6v4U448TVLKi8J9hG4w%2FAc08%2BWGD7rrgswoO3gEj8uINh12MZQCA0In%2FW4PvQAC0J4OSSUIs9%2BqqGm%2FBtGA7bv&webInteractiveContentId=412216133822&portalId=25734893&hsLang=en) Toggle Menu Search Toggle Menu [![Request a conversation](https://hubspot-no-cache-eu1-prod.s3.amazonaws.com/cta/default/25734893/interactive-412216133822.png)](https://simsendiagnostics.com/hs/cta/wi/redirect?encryptedPayload=AVxigLI1AWeK9%2FmXQcEF4ftmAPshFd4S580Jel%2FweBTsGsgqXdHWCDRoauEhOtNx80XRb8O96rI6cwBaWFkVISbd46oDDS1bDylKAfW6ERCgn%2FHz1CmawL6v4U448TVLKi8J9hG4w%2FAc08%2BWGD7rrgswoO3gEj8uINh12MZQCA0In%2FW4PvQAC0J4OSSUIs9%2BqqGm%2FBtGA7bv&webInteractiveContentId=412216133822&portalId=25734893&hsLang=en) - [PLATFORM](https://simsendiagnostics.com/platform) - [Why Simsen](https://simsendiagnostics.com/why-simsen) - [Our technology](https://simsendiagnostics.com/platform-our-technology) - [Methodology](https://simsendiagnostics.com/platform-methodology) - [Find your approach](https://simsendiagnostics.com/find-your-approach) - [Delivered your way](https://simsendiagnostics.com/both-delivery-models) - [Solutions](https://simsendiagnostics.com/solutions-overview) - [EVIDENCE](https://simsendiagnostics.com/evidence-hub) - [Publications](https://simsendiagnostics.com/evidence-publications) - [Paediatric solid tumours](https://simsendiagnostics.com/evidence-paediatric-solid-tumours) - [CNS tumours & CSF ctDNA](https://simsendiagnostics.com/evidence-cns-csf-ctdna) - [White papers](https://simsendiagnostics.com/evidence-white-paper-ctdna-trials) - [COMPANY](https://simsendiagnostics.com/company-about) - [About us](https://simsendiagnostics.com/company-about) - [Team](https://simsendiagnostics.com/company-team) - [Contact us](https://simsendiagnostics.com/company-contact) - [News](https://simsendiagnostics.com/news) - [RESOURCES](https://simsendiagnostics.com/resources-hub) - [Sample collection guides](https://simsendiagnostics.com/resources-sample-collection-guides) - [Baseline kit guide](https://simsendiagnostics.com/baseline-collection-kit) - [Follow-up kit guide](https://simsendiagnostics.com/resources-followup-collection-kit) [For clinical trials Pharma and CROs Validate MRD endpoints, cut trial-arm cost, build EU regulatory readiness. Design a trial assay →](https://simsendiagnostics.com/solutions-trials?hsLang=en) [For research and labs Translational oncology See signal in paediatric and early-stage samples your current platform misses. Send samples or run SiMSen-Seq in-house. See the signal →](https://simsendiagnostics.com/solutions-research?hsLang=en) [For clinics Premium oncology monitoring Detect minimal residual disease ahead of imaging. Logistics across the EU, UK and EEA. Detect relapse earlier →](https://simsendiagnostics.com/solutions-clinic?hsLang=en) [Home](https://simsendiagnostics.com?hsLang=en) / [Platform](https://simsendiagnostics.com/platform?hsLang=en) / Why Simsen Why choose Simsen # Ultra-sensitive ctDNA delivered *your way*. Five reasons researchers, pharma teams and clinics across Europe choose to work with us. Each pillar is a customer outcome first, a Simsen capability second. [Sensitivity](https://simsendiagnostics.com/why-simsen#sensitivity_01) [Flexibility](https://simsendiagnostics.com/why-simsen#flexibility_02) [Clinical insight](https://simsendiagnostics.com/why-simsen#clinical_03) [Transparency](https://simsendiagnostics.com/why-simsen#transparency_04) [Partnership](https://simsendiagnostics.com/why-simsen#partnership_05) 01 Sensitivity ### You detect signal at parts-per-million, in samples your current platform calls negative. **SiMSen-Seq chemistry, with molecular barcoding (unique molecular identifiers) and error suppression, separates true variants from background noise. Tracking a personalised panel of 20 to 30 variants reaches MRD sensitivity around 0.001% VAF, the regime where most ctDNA platforms run out of resolution and start returning false negatives.** For minimal residual disease monitoring, that resolution is what determines whether you see a relapse three months before imaging does, or three months after the patient does. For early-stage and paediatric samples, with low tumour burden in low blood volume, it is what determines whether you can run the assay at all. This is the foundational claim under everything else on the platform. Without it, the rest does not matter. 02 Flexibility ### You choose: send samples to our lab, or run SiMSen-Seq on your own instruments. **Two delivery models. Same chemistry, same sensitivity, same data quality. The decision is operational, not scientific.** Send samples to the Simsen lab when you want the turnaround and the interpretation done for you. Bring SiMSen-Seq in-house with LabSuite when you have the bench capacity, want full control of the workflow, or are running volumes that justify an internal pipeline. This is the foundational claim under everything else on the platform. Without it, the rest does not matter. 03 Clinical insight ### You see actionable variants and tumour evolution, not just a binary positive or negative. **The output is a clinical view of what is happening in the tumour, not a flag in a database.** Personalised ctDNA panels track the variants that matter for the individual patient and the tumour type, and surface resistance markers and clonal evolution over time. The report is built for the people reading it: clinicians, principal investigators, study teams. Each variant has a clinical rationale, not just a score. If the question is "is there residual disease, yes or no", we will answer it. If the question is "what is the tumour doing now, and what should we change", the platform was built for that one. 04 Transparency ### You get full raw data access and an open analysis pipeline. Your bioinformatics team can verify, reanalyse or extend our results with their own tools. **No black-box scoring. No hidden variant call adjustments. The pipeline is open, the assumptions are documented, and the raw data is yours.** For translational research groups and pharma analytics teams, this is non-negotiable. You need to be able to reproduce the call, run a second pipeline against the same data, and publish without a vendor sitting between you and the result. We work that way by default. It also means we get told when our pipeline is wrong. We prefer that to the alternative. 05 Partnership ### You work with a specialist team: co-publication, protocol design and interpretation help. **A small team of ctDNA specialists, in your time zone, who have already run samples like yours.** Co-authorship on the resulting paper, where the science supports it. Protocol design help up front, when an early conversation can save a sample run later. Interpretation help when a result is unusual and you want a second set of eyes on it. We are not the right partner for every project. We are an exceptionally good partner for the ones we are right for. In your language ### The same five pillars sound different depending on who is reading them. Each Solutions page retells these pillars in the language of the people on that side of the bench. Pick yours For clinical trials ### Cost saving on trial arms, MRD endpoints that hold up, co-publication. The five pillars in pharma and CRO terms: cohort-level cost saving, validated MRD endpoints, regulatory readiness in the EU, raw data for your analytics teams, and co-authorship on the resulting paper. [READ THE PHARMA PAGE →](https://simsendiagnostics.com/solutions-trials?hsLang=en) For research & Labs ### Low-AF detection, instrument-agnostic kits, raw data, co-authorship. The five pillars in translational oncology terms: detection in paediatric and early-stage samples, LabSuite on the instruments you already own, full pipeline transparency, and shared bylines. [READ THE RESEARCH PAGE →](https://simsendiagnostics.com/solutions-research?hsLang=en) For clinics ### Premium monitoring, lead time over imaging, EU logistics, real support. The five pillars in clinic terms: personalised ctDNA monitoring for individual patients, earlier signal than imaging, logistics across Europe, and a specialist team that picks up the phone. [READ THE CLINICS PAGE →](https://simsendiagnostics.com/solutions-clinic?hsLang=en) Next on the platform ## If Why Simsen lands, here is where to go next. Technology ### SiMSen-Seq, the science under the hood. Barcoded sequencing with unique molecular identifiers (UMIs), error suppression and the sample-to-result workflow, with performance data. [Read the technology page →](https://simsendiagnostics.com/platform-our-technology?hsLang=en) Comparison ### SNV vs SV vs tumour-naive The three families of tumour-informed monitoring, side by side, and a four-question decision guide. [Compare the methodologies →](https://simsendiagnostics.com/platform-methodology?hsLang=en) Delivery models ### Full-service lab or LabSuite kits. The two delivery models, the trade-offs on cost, control, turnaround and capability. [See both delivery models →](https://simsendiagnostics.com/both-delivery-models?hsLang=en) Talk to us ### Speak to our scientific team A real human, in CET/CEST time zone, who has run samples like yours. [inbox@simsendiagnostics.com](mailto:inbox@simsendiagnostics.com) [Request a conversation →](https://simsendiagnostics.com/start-a-conversation?hsLang=en)     ![full_lockup_white_CMYK kopia](https://simsendiagnostics.com/hs-fs/hubfs/full_lockup_white_CMYK%20kopia.png?width=166&height=45&name=full_lockup_white_CMYK%20kopia.png) **Visiting and postal address:** Pepparedsleden 1 431 53 Mölndal, Sweden **Shipping address:** c/o AstraZeneca R&D Mölndal Pepparedsleden 3 431 53 Mölndal, Sweden PLATFORM PLATFORM - [Platform overview](https://simsendiagnostics.com/platform) - [Why Simsen](https://simsendiagnostics.com/why-simsen) - [Our technology](https://simsendiagnostics.com/platform-our-technology) - [Delivered your way](https://simsendiagnostics.com/both-delivery-models) SOLUTIONS SOLUTIONS - [For clinical trials](https://simsendiagnostics.com/solutions-trials) - [For research and labs](https://simsendiagnostics.com/solutions-research) - [For clinics](https://simsendiagnostics.com/solutions-clinic) - [Solutions overview](https://simsendiagnostics.com/solutions-overview) COMPANY COMPANY - [About](https://simsendiagnostics.com/company-about) - [News](https://simsendiagnostics.com/news) - [Team](https://simsendiagnostics.com/company-team) - [Contact](https://simsendiagnostics.com/company-contact) - [Privacy policy](https://simsendiagnostics.com/legal-privacy-policy) - [Cookie Policy](https://simsendiagnostics.com/legal-cookie-policy) - [Terms of use](https://simsendiagnostics.com/legal-terms-of-use) © 2026 Simsen Diagnostics AB, All rights reserved. [Linkedin](https://www.linkedin.com/company/simsendiagnostics) Return to top